Cataract Surgery

SURF-201 meets primary endpoints for the treatment of post-cataract pain, inflammation

SURF-201 (Surface Ophthalmics, Inc) met its primary endpoints of absence of inflammation at day 8 and day 15, according to top-line results from a Phase 2 trial. In the trial, 91 patients who underwent cataract surgery received twice-daily dosing of SURF-201. The primary endpoints of complete clearance of anterior chamber...